{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T15:53:30Z","timestamp":1777650810773,"version":"3.51.4"},"reference-count":29,"publisher":"Frontiers Media SA","issue":"11","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1121,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1111\/j.1432-2277.2012.01540.x","type":"journal-article","created":{"date-parts":[[2012,8,6]],"date-time":"2012-08-06T10:16:05Z","timestamp":1344248165000},"page":"1158-1164","source":"Crossref","is-referenced-by-count":54,"title":["High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation"],"prefix":"10.3389","volume":"25","author":[{"given":"Katharina","family":"Staufer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lutz","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Seegers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eik","family":"Vettorazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bjoern","family":"Nashan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Sterneck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2012,8,6]]},"reference":[{"key":"10.1111\/j.1432-2277.2012.01540.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/lt.21738","article-title":"Improved results of transplantation for hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation","volume":"15","author":"Onaca","year":"2009","journal-title":"Liver Transpl"},{"issue":"Suppl. 2","key":"10.1111\/j.1432-2277.2012.01540.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1002\/lt.22361","article-title":"Treatment of recurrent hepatocellular carcinoma after liver transplantation","volume":"17","author":"Davis","year":"2011","journal-title":"Liver Transpl"},{"key":"10.1111\/j.1432-2277.2012.01540.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/17401","article-title":"Cyclosporine induces cancer progression by a cell-autonomous mechanism","volume":"397","author":"Hojo","year":"1999","journal-title":"Nature"},{"key":"10.1111\/j.1432-2277.2012.01540.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/00007890-199902270-00003","article-title":"Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma","volume":"67","author":"Freise","year":"1999","journal-title":"Transplantation"},{"key":"10.1111\/j.1432-2277.2012.01540.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1158\/1078-0432.CCR-07-4774","article-title":"Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma","volume":"14","author":"Wang","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1111\/j.1432-2277.2012.01540.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor","volume":"8","author":"Guba","year":"2002","journal-title":"Nat Med"},{"issue":"Suppl. 2","key":"10.1111\/j.1432-2277.2012.01540.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"S159","DOI":"10.1002\/lt.22318","article-title":"Immunosuppression and hepatocellular carcinoma","volume":"17","author":"Schlitt","year":"2011","journal-title":"Liver Transpl"},{"key":"10.1111\/j.1432-2277.2012.01540.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1002\/lt.21953","article-title":"Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation","volume":"15","author":"Chinnakotla","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1111\/j.1432-2277.2012.01540.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1432-2277.2007.00505.x","article-title":"Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: a single-center experience","volume":"20","author":"Zimmerman","year":"2007","journal-title":"Transplant Int"},{"key":"10.1111\/j.1432-2277.2012.01540.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/hep.23437","article-title":"Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma","volume":"51","author":"Toso","year":"2010","journal-title":"Hepatology"},{"key":"10.1111\/j.1432-2277.2012.01540.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/1471-2407-10-190","article-title":"A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma","volume":"10","author":"Schnitzbauer","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1111\/j.1432-2277.2012.01540.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"New Engl J Med"},{"key":"10.1111\/j.1432-2277.2012.01540.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.transproceed.2010.02.014","article-title":"Management of hepatocellular carcinoma recurrence after liver transplantation","volume":"42","author":"Valdivieso","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1111\/j.1432-2277.2012.01540.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1440-1746.2008.05672.x","article-title":"Palliative chemotherapy for patients with recurrent hepatocellular carcinoma after liver transplantation","volume":"24","author":"Lee","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1111\/j.1432-2277.2012.01540.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/jjco\/hyq055","article-title":"Sorafenib for recurrent hepatocellular carcinoma after liver transplantation","volume":"40","author":"Yoon","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"10.1111\/j.1432-2277.2012.01540.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jhep.2010.01.025","article-title":"Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle","volume":"52","author":"Bhoori","year":"2010","journal-title":"J Hepatol"},{"key":"10.1111\/j.1432-2277.2012.01540.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1111\/j.1600-6143.2009.02860.x","article-title":"Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib","volume":"9","author":"Yeganeh","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1432-2277.2012.01540.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1007\/s12032-010-9625-x","article-title":"Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection","volume":"28","author":"Kim","year":"2011","journal-title":"Med Oncol"},{"key":"10.1111\/j.1432-2277.2012.01540.x-BIB19|cit19","first-page":"4951","article-title":"PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras\/Raf\/MAPK and PI3K\/AKT\/mTOR pathways","volume":"30","author":"Gedaly","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1111\/j.1432-2277.2012.01540.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jhep.2009.03.028","article-title":"Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo","volume":"51","author":"Newell","year":"2009","journal-title":"J Hepatol"},{"key":"10.1111\/j.1432-2277.2012.01540.x-BIB21|cit21","unstructured":"Institute NC Common Terminology Criteria for Adverse Events v3.0 (CTCAE)"},{"key":"10.1111\/j.1432-2277.2012.01540.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1177\/030089161109700404","article-title":"Recurrent hepatocellular carcinoma in liver transplant recipients: parameters affecting time to recurrence, treatment options and survival in the sorafenib era","volume":"97","author":"Pfiffer","year":"2011","journal-title":"Tumori"},{"key":"10.1111\/j.1432-2277.2012.01540.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/jjco\/hyq055","article-title":"Sorafenib for recurrent hepatocellular carcinoma after liver transplantation","volume":"40","author":"Yoon","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"10.1111\/j.1432-2277.2012.01540.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1159\/000319548","article-title":"Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation","volume":"79","author":"Kim","year":"2010","journal-title":"Oncology"},{"key":"10.1111\/j.1432-2277.2012.01540.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/lt.22434","article-title":"Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation","volume":"18","author":"Gomez-Martin","year":"2012","journal-title":"Liver Transpl"},{"key":"10.1111\/j.1432-2277.2012.01540.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/TP.0b013e3181daac69","article-title":"Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient","volume":"90","author":"Herden","year":"2010","journal-title":"Transplantation"},{"key":"10.1111\/j.1432-2277.2012.01540.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/ajg.2008.41","article-title":"Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib","volume":"104","author":"Llanos","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1432-2277.2012.01540.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1111\/j.1572-0241.2008.01982_19.x","article-title":"Sorafenib-induced liver failure","volume":"103","author":"Schramm","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1432-2277.2012.01540.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s12029-010-9196-2","article-title":"Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation","volume":"42","author":"Kim","year":"2011","journal-title":"J Gastrointest Cancer"}],"container-title":["Transplant International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1432-2277.2012.01540.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1432-2277.2012.01540.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T18:35:54Z","timestamp":1641062154000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1432-2277.2012.01540.x"}},"subtitle":["High toxicity of sorafenib after liver transplantation"],"short-title":[],"issued":{"date-parts":[[2012,8,6]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1432-2277.2012.01540.x","relation":{},"ISSN":["0934-0874"],"issn-type":[{"value":"0934-0874","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8,6]]}}}